Compare
RadNet, Inc. vs Guardant Health, Inc. vs Caris Life Sciences, Inc. vs Quest Diagnostics Inc
| Latest fiscal year | RadNet, Inc. RDNT | Guardant Health, Inc. GH | Caris Life Sciences, Inc. CAI | Quest Diagnostics Inc DGX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.04B | $982.02M | $812.03M | $11.04B |
| Revenue growth (YoY) | +11.5% | +32.9% | +97.0% | +11.8% |
| Gross margin | n/a | 64.5% (computed) | n/a | 33.2% (computed) |
| Operating margin | 3.0% | -44.5% | 5.6% | 14.1% |
| Net margin | -0.9% | -42.4% | -8.4% | 9.0% |
| Net income | -$18.65M | -$416.28M | -$68.09M | $992.00M |
| EPS (Diluted) | -$0.25 | -$3.32 | -$3.22 | $8.75 |
| Operating cash flow | $298.82M | -$184.76M | $83.16M | $1.89B |
| Free cash flow | n/a | -$233.07M | $66.89M | $1.36B |
| Cash & equivalents | $767.22M | $378.20M | $796.27M | $420.00M |
| Total assets | $3.76B | $2.01B | $1.13B | $16.23B |
| Total liabilities | $2.40B | $2.11B | $548.36M | n/a |
| Shareholders' equity | $1.36B | -$99.31M | $577.31M | $7.21B |
| Return on year-end equity | -1.4% | n/a | -11.8% | 13.8% |
| Shares outstanding | 74.04M | 130.64M | 282.53M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | RadNet, Inc. | Guardant Health, Inc. | Caris Life Sciences, Inc. | Quest Diagnostics Inc |
|---|---|---|---|---|
| Latest | $2.04B Ended 2025-12-31 | $982.02M Ended 2025-12-31 | $812.03M Ended 2025-12-31 | $11.04B Ended 2025-12-31 |
| 1 year earlier | $1.83B Ended 2024-12-31 | $739.02M Ended 2024-12-31 | $412.26M Ended 2024-12-31 | $9.87B Ended 2024-12-31 |
| 2 years earlier | $1.62B Ended 2023-12-31 | $563.95M Ended 2023-12-31 | $306.13M Ended 2023-12-31 | $9.25B Ended 2023-12-31 |
| 3 years earlier | $1.43B Ended 2022-12-31 | $449.54M Ended 2022-12-31 | n/a | $9.88B Ended 2022-12-31 |
| 4 years earlier | $1.32B Ended 2021-12-31 | $373.65M Ended 2021-12-31 | n/a | $10.79B Ended 2021-12-31 |